Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
EqualOcean | Southern Weekly 2022 'China Greenwashing List'
Yesterday 12:37 PM
2022 ESG Report Analysis | Yili: The Practical Path of ESG
Sep 28, 2023 09:01 PM
An Analysis of Domestic ESG Rating Agencies in China
Sep 28, 2023 12:46 PM